Rezolute, Inc. announced full enrollment in its Phase 3 upLIFT study testing ersodetug for tumor hyperinsulinism, a rare cause of severe hypoglycemia. The study involves 16 patients with insulinoma or non-islet cell tumors and aims to reduce intravenous glucose needs by at least 50%. Early results showed promising responses and good safety. Topline data are expected by mid-December 2026, potentially advancing treatment options for this serious condition.
Rezolute's Phase 3 upLIFT study enrollment completion offers context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Oct 15, 2026 03:02 WIB: Among 150 priced US health-sector stocks tradable on Pluang, 90 rose and 60 fell today. Notable movers include HALO at USD 116.86 with a 1-day change of +6.60% and Pluang order activity showing 71% Buy, BFLY at USD 7.62 down 5.93% with 100% Buy activity, and CGC at USD 0.72 down 5.60% with 98% Sell activity.
Stephany Insurance LLC, a fourth-generation independent agency in Wexford, PA, is highlighted in a new 2026 guide for helping small businesses in Pittsburgh's North Hills identify and close insurance coverage gaps caused by rising premiums. The guide...
The Knowles-Rowland House, a $13.96 million redevelopment project by Bread of Life Inc., has opened in Midtown Houston, providing 31 permanent supportive housing units for individuals exiting chronic homelessness. The building, formerly a fire-damage...
ATLAS SP Partners, majority owned by Apollo funds, announced the pricing of $750 million senior notes due 2032 with a fixed 6.25% interest rate until November 2031, then switching to a floating rate based on SOFR plus a spread. The notes, issued by A...
Bending Spoons led market gainers with a 41.2% rise after Berkshire Hathaway increased its stake to 4% by investing an additional $330 million. Antelope Enterprise gained 36.4%, and NEXGEL rose 32.1% following a reverse stock split. Liquidia advanced...
The Law Offices of Frank R. Cruz is investigating Alignment Healthcare following a whistleblower lawsuit claiming the company misclassified $8-10 million in expenses to inflate its adjusted EBITDA and stock price. This alleged accounting manipulation...
